Adia Nutrition Reports Over 200% Revenue Growth and Advances Toward Nasdaq Uplisting

Reuters
2025/12/29
<a href="https://laohu8.com/S/ADIA">Adia Nutrition</a> Reports Over 200% Revenue Growth and Advances Toward Nasdaq Uplisting

Adia Nutrition Inc. (OTCQB: ADIA) reported significant business milestones and financial results for 2025. The company achieved a successful uplisting from OTC Pink to the OTCQB Venture Market in six weeks and completed SEC Rule 15c2-11 compliance. Preliminary and confirmed Q3 results indicated revenue growth of over 200% quarter-over-quarter, with earlier reports showing more than 100% growth and profit margins exceeding 20%. The sales force was tripled, and four regional sales divisions were established. Adia became a preferred vendor for the PI Doctors Elite Community, gaining access to over 4,000 personal injury physicians and the $50 billion personal injury care market. The company launched a national television marketing campaign and divested its Biolete Coffee subsidiary while retaining an 18% equity stake. Adia also progressed in negotiations for in-network status with major insurance providers and filed an SEC Form 10, with Nasdaq uplisting approval expected in early 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adia Nutrition Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 279037) on December 29, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10